Adenomatous Polyposis Syndromes: Polymerase Proofreading-Associated Polyposis

Chapter

Abstract

POLE and POLD1 encode the major subunits of polymerase ε and polymerase δ, respectively. Missense germline mutations in the exonuclease domains (EDMs) of POLE and POLD1 have been found to be a rare cause of multiple colorectal adenomas and carcinomas. This condition is known as polymerase proofreading-associated polyposis (PPAP). The EDM of POLE is also somatically mutated in ~1% of colorectal cancers (CRCs) and ~8% of endometrial cancers. In this chapter we will consider the roles of these two enzymes, germline mutations that have been identified to date and their pathogenicity, the characteristics of tumours with germline or somatic mutations, clinical characteristics of patients with PPAP and the potential use of immunotherapy in patients with mutations in the EDM of POLE.

Keywords

PPAP Adenomatous polyposis Exonuclease Polymerase epsilon Polymerase delta DNA repair Genetic testing Genetic counselling Hereditary cancer 

References

  1. 1.
    Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2013;45(2):136–44.  https://doi.org/10.1038/ng.2503.CrossRefPubMedGoogle Scholar
  2. 2.
    Aoude LG, Heitzer E, Johansson P, Gartside M, Wadt K, Pritchard AL, et al. POLE mutations in families predisposed to cutaneous melanoma. Familial Cancer. 2015;14(4):621–8.  https://doi.org/10.1007/s10689-015-9826-8.CrossRefPubMedGoogle Scholar
  3. 3.
    Bellido F, Pineda M, Aiza G, Valdes-Mas R, Navarro M, Puente DA, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325–32.  https://doi.org/10.1038/gim.2015.75.CrossRefPubMedGoogle Scholar
  4. 4.
    Chubb D, Broderick P, Frampton M, Kinnersley B, Sherborne A, Penegar S, et al. Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing. J Clin Oncol. 2015;33(5):426–32.  https://doi.org/10.1200/JCO.2014.56.5689.CrossRefPubMedGoogle Scholar
  5. 5.
    Elsayed FA, Kets CM, Ruano D, van den Akker B, Mensenkamp AR, Schrumpf M, et al. Germline variants in POLE are associated with early onset mismatch repair deficient colorectal cancer. Eur J Hum Genet. 2015;23(8):1080–4.CrossRefGoogle Scholar
  6. 6.
    Hansen MF, Johansen J, Bjornevoll I, Sylvander AE, Steinsbekk KS, Saetrom P, et al. A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestine. Familial Cancer. 2015;14(3):437–48.  https://doi.org/10.1007/s10689-015-9803-2.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Rohlin A, Eiengard F, Lundstam U, Zagoras T, Nilsson S, Edsjo A, et al. GREM1 and POLE variants in hereditary colorectal cancer syndromes. Genes Chromosom Cancer. 2016;55(1):95–106.  https://doi.org/10.1002/gcc.22314.CrossRefPubMedGoogle Scholar
  8. 8.
    Rohlin A, Zagoras T, Nilsson S, Lundstam U, Wahlstrom J, Hulten L, et al. A mutation in POLE predisposing to a multi-tumour phenotype. Int J Oncol. 2014;45(1):77–81.  https://doi.org/10.3892/ijo.2014.2410.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Spier I, Holzapfel S, Altmuller J, Zhao B, Horpaopan S, Vogt S, et al. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int J Cancer. 2015;137(2):320–31.  https://doi.org/10.1002/ijc.29396.CrossRefPubMedGoogle Scholar
  10. 10.
    Valle L, Hernandez-Illan E, Bellido F, Aiza G, Castillejo A, Castillejo MI, et al. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Hum Mol Genet. 2014;23(13):3506–12.  https://doi.org/10.1093/hmg/ddu058.CrossRefPubMedGoogle Scholar
  11. 11.
    Wimmer K, Beilken A, Nustede R, Ripperger T, Lamottke B, Ure B, et al. A novel germline POLE mutation causes an early onset cancer prone syndrome mimicking constitutional mismatch repair deficiency. Familial Cancer. 2017;16(1):67–71.CrossRefGoogle Scholar
  12. 12.
    Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21.  https://doi.org/10.1038/nature12477.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Shevelev IV, Hubscher U. The 3′ 5′ exonucleases. Nat Rev Mol Cell Biol. 2002;3(5):364–76.  https://doi.org/10.1038/nrm804.CrossRefPubMedGoogle Scholar
  14. 14.
    McCulloch SD, Kunkel TA. The fidelity of DNA synthesis by eukaryotic replicative and translesion synthesis polymerases. Cell Res. 2008;18(1):148–61.  https://doi.org/10.1038/cr.2008.4.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Nick McElhinny SA, Gordenin DA, Stith CM, Burgers PM, Kunkel TA. Division of labor at the eukaryotic replication fork. Mol Cell. 2008;30(2):137–44.  https://doi.org/10.1016/j.molcel.2008.02.022.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Derbyshire V, Grindley ND, Joyce CM. The 3′-5′ exonuclease of DNA polymerase I of Escherichia coli: contribution of each amino acid at the active site to the reaction. EMBO J. 1991;10(1):17–24.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Murphy K, Darmawan H, Schultz A, Fidalgo da Silva E, Reha-Krantz LJ. A method to select for mutator DNA polymerase deltas in Saccharomyces cerevisiae. Genome. 2006;49(4):403–10.  https://doi.org/10.1139/g05-106.CrossRefPubMedGoogle Scholar
  18. 18.
    Shinbrot E, Henninger EE, Weinhold N, Covington KR, Goksenin AY, Schultz N, et al. Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. Genome Res. 2014;24(11):1740–50.CrossRefGoogle Scholar
  19. 19.
    Rayner E, van Gool IC, Palles C, Kearsey SE, Bosse T, Tomlinson I, et al. A panoply of errors: polymerase proofreading domain mutations in cancer. Nature Rev. 2016;16(2):71–81.Google Scholar
  20. 20.
    Esteban-Jurado C, Gimenez-Zaragoza D, Munoz J, Franch-Exposito S, Alvarez-Barona M, Ocana T, et al. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer. Oncotarget. 2017;8(16):26732–43.  https://doi.org/10.18632/oncotarget.15810.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Shlien A, Campbell BB, de Borja R, Alexandrov LB, Merico D, Wedge D, et al. Combined hereditary and somatic mutations of replication error repair genes result in rapid onset of ultra-hypermutated cancers. Nat Genet. 2015;47(3):257–62.  https://doi.org/10.1038/ng.3202.CrossRefPubMedGoogle Scholar
  22. 22.
    Church DN, Briggs SE, Palles C, Domingo E, Kearsey SJ, Grimes JM, et al. DNA polymerase epsilon and delta exonuclease domain mutations in endometrial cancer. Hum Mol Genet. 2013;22(14):2820–8.CrossRefGoogle Scholar
  23. 23.
    Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.CrossRefGoogle Scholar
  24. 24.
    Church DN, Stelloo E, Nout RA, Valtcheva N, Depreeuw J, ter Haar N, et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst. 2015;107(1):402.CrossRefGoogle Scholar
  25. 25.
    Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113(2):299–310.CrossRefGoogle Scholar
  26. 26.
    Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7.CrossRefGoogle Scholar
  27. 27.
    Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, et al. Recurrent R-spondin fusions in colon cancer. Nature. 2012;488(7413):660–4.CrossRefGoogle Scholar
  28. 28.
    Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Lancet. 2016;1(3):207–16.PubMedGoogle Scholar
  29. 29.
    Zou Y, Liu FY, Liu H, Wang F, Li W, Huang MZ, et al. Frequent POLE1 p.S297F mutation in Chinese patients with ovarian endometrioid carcinoma. Mutat Res. 2014;761:49–52.CrossRefGoogle Scholar
  30. 30.
    Erson-Omay EZ, Caglayan AO, Schultz N, Weinhold N, Omay SB, Ozduman K, et al. Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. Neuro-Oncology. 2015;17(10):1356–64.CrossRefGoogle Scholar
  31. 31.
    Briggs S, Tomlinson I. Germline and somatic polymerase epsilon and delta mutations define a new class of hypermutated colorectal and endometrial cancers. J Pathol. 2013;230(2):148–53.CrossRefGoogle Scholar
  32. 32.
    Kane DP, Shcherbakova PV. A common cancer-associated DNA polymerase epsilon mutation causes an exceptionally strong mutator phenotype, indicating fidelity defects distinct from loss of proofreading. Cancer Res. 2014;74(7):1895–901.CrossRefGoogle Scholar
  33. 33.
    Heitzer E, Tomlinson I. Replicative DNA polymerase mutations in cancer. Curr Opin Genet Dev. 2014;24:107–13.CrossRefGoogle Scholar
  34. 34.
    Billingsley CC, Cohn DE, Mutch DG, Stephens JA, Suarez AA, Goodfellow PJ. Polymerase varepsilon (POLE) mutations in endometrial cancer: clinical outcomes and implications for lynch syndrome testing. Cancer. 2014;121(3):386–94.CrossRefGoogle Scholar
  35. 35.
    Sole RV, Deisboeck TS. An error catastrophe in cancer? J Theor Biol. 2004;228(1):47–54.CrossRefGoogle Scholar
  36. 36.
    Loeb LA. Human cancers express mutator phenotypes: origin, consequences and targeting. Nature Rev. 2011;11(6):450–7.Google Scholar
  37. 37.
    Herr AJ, Ogawa M, Lawrence NA, Williams LN, Eggington JM, Singh M, et al. Mutator suppression and escape from replication error-induced extinction in yeast. PLoS Genet. 2011;7(10):e1002282.CrossRefGoogle Scholar
  38. 38.
    Williams LN, Herr AJ, Preston BD. Emergence of DNA polymerase epsilon antimutators that escape error-induced extinction in yeast. Genetics. 2013;193(3):751–70.CrossRefGoogle Scholar
  39. 39.
    Meng B, Hoang LN, McIntyre JB, Duggan MA, Nelson GS, Lee CH, et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol Oncol. 2014;134(1):15–9.CrossRefGoogle Scholar
  40. 40.
    Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol. 2015;28(6):836–44.CrossRefGoogle Scholar
  41. 41.
    Hussein YR, Weigelt B, Levine DA, Schoolmeester JK, Dao LN, Balzer BL, et al. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod Pathol. 2015;28(4):505–14.CrossRefGoogle Scholar
  42. 42.
    Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482(7385):400–4.CrossRefGoogle Scholar
  43. 43.
    DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature. 2012;482(7385):405–9.CrossRefGoogle Scholar
  44. 44.
    van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013;31(32):e439–42.CrossRefGoogle Scholar
  45. 45.
    van Gool IC, Eggink FA, Freeman-Mills L, Stelloo E, Marchi E, de Bruyn M, et al. POLE proofreading mutations elicit an antitumor immune response in endometrial cancer. Clin Cancer Res. 2015;21(14):3347–55.CrossRefGoogle Scholar
  46. 46.
    van Gool IC, Bosse T, Church DN. POLE proofreading mutation, immune response and prognosis in endometrial cancer. Oncoimmunology. 2016;5(3):e1072675.CrossRefGoogle Scholar
  47. 47.
    Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.CrossRefGoogle Scholar
  48. 48.
    Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, et al. Immunogenomics of Hypermutated Glioblastoma: a patient with Germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov. 2016;6(11):1230–6.CrossRefGoogle Scholar
  49. 49.
    Santin AD, Bellone S, Buza N, Choi J, Schwartz PE, Schlessinger J, et al. Regression of chemotherapy-resistant polymerase epsilon (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab. Clin Cancer Res. 2016;22(23):5682–7.CrossRefGoogle Scholar
  50. 50.
    Piulats JM, Matias-Guiu X. Immunotherapy in endometrial cancer: in the Nick of time. Clin Cancer Res. 2016;22(23):5623–5.CrossRefGoogle Scholar
  51. 51.
    Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819–29.CrossRefGoogle Scholar
  52. 52.
    Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–7.CrossRefGoogle Scholar
  53. 53.
    Dovedi SJ, Cheadle EJ, Popple A, Poon E, Morrow M, Stewart R, et al. Fractionated radiation therapy stimulates anti-tumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD1 blockade. Clin Cancer Res. 2017;23(18):5514–26.CrossRefGoogle Scholar
  54. 54.
    Spier I, Holzapfel S, Altmuller J, Zhao B, Horpaopan S, Vogt S, et al. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int J Cancer. 2014;137(2):320–31.CrossRefGoogle Scholar
  55. 55.
    Sinha A, Tekkis PP, Rashid S, Phillips RK, Clark SK. Risk factors for secondary proctectomy in patients with familial adenomatous polyposis. Br J Surg. 2010;97(11):1710–5.CrossRefGoogle Scholar
  56. 56.
    Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62(6):812–23.CrossRefGoogle Scholar
  57. 57.
    Jansen AM, van Wezel T, van den Akker BE, Ventayol Garcia M, Ruano D, Tops CM, et al. Combined mismatch repair and POLE/POLD1 defects explain unresolved suspected Lynch syndrome cancers. Eur J Hum Genet. 2016;24(7):1089–92.  https://doi.org/10.1038/ejhg.2015.252.CrossRefPubMedGoogle Scholar
  58. 58.
    Abdus Sattar AK, Lin TC, Jones C, Konigsberg WH. Functional consequences and exonuclease kinetic parameters of point mutations in bacteriophage T4 DNA polymerase. Biochemistry. 1996;35(51):16621–9.  https://doi.org/10.1021/bi961552q.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institute of Cancer and Genomic Sciences, University of BirminghamBirminghamUK
  2. 2.The Polyposis Registry, St Mark’s HospitalHarrow, LondonUK
  3. 3.Department of Surgery and Cancer, Imperial College LondonHarrow, LondonUK
  4. 4.Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL and CIBERONC, Hospitalet de LlobregatBarcelonaSpain

Personalised recommendations